Genprex's Leading Drug Candidate Is Currently Being Developed As A Treatment For Lung Cancer

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. Genprex was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020.According to data from the World Health Organization, cancer is currently the second leading cause of death worldwide, and unfortunately, this number is only expected to rise. In 2018, the total number of cancer-related deaths globally was 9.5 million. And by 2040, this number is expected to increase to 16.4 million. Due to this growing number, many clinical research companies have been looking for ways to help fight against this disease. Founded in 2009, Genprex Inc (NASDAQ:GNPX) is a clinical-stage gene therapy company that’s developing therapies for patients with cancer and diabetes. The company works with world-class institutions and collaborators to provide novel treatment approaches. “Genprex is dedicated in our efforts to help patients with limited or no treatment options have access to new and advanced therapies to treat their disease. Genprex’s vision is a world where serious disease is treated at its source to actually change the course of the disease, rather than merely treating symptoms,” said Rodney Varner, CEO of Genprex. Leading Drug Candidate REQORSA™, Genprex’s leading drug candidate, is an immunogene therapy that is currently being developed as To keep reading about Genprex's Leading Drug Candidate Is Currently Being Developed As A Treatment For Lung Cancer, Click on the link. Seoul, Korea
http://dlvr.it/Rp8qrc

Comments

Post a Comment

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Image
(RTTNews) - AstraZeneca Plc (AZN.L, AZN) said first participants have been dosed in a Phase I trial of AZD7442 for the prevention and treatment of COVID-19. The trial will evaluate the safety, tolerability and pharmacokinetics of AZD7442. It will include up to 48 healthy participants in the UK aged 18 to 55 years. AZD7442 is a combination of two monoclonal antibodies derived from convalescent patients with SARS-CoV-2 infection. Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the mAbs were optimised by AstraZeneca. Data readout from the trial is anticipated in the second half of 2020. To keep reading about AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts, Click on the link. Seoul, Korea http://dlvr.it/RfHgSK
Read more

Coronavirus Hasn't Diminished Tech Stocks' Allure

Image
FYI: By Caitlin McCabe Caitlin McCabe The Wall Street Journal Biography caitlin.mccabe@wsj.com Updated April 20, 2020 6:14 pm ET The FANG trade hasn’t lost its bite. Big technology stocks are again charging to new heights and propelling the broader stock market, which is swiftly rebounding after a punishing selloff. The NYSE FANG+ index—which comprises Facebook Inc., FB -0.56% Amazon.com Inc., AMZN 0.78% Netflix Inc. NFLX 3.44% and Google parent Alphabet Inc., GOOG -1.30% along with Apple Inc., AAPL -2.08% Twitter Inc., Tesla Inc., TSLA -1.00% Nvidia Corp. NVDA -1.80% and the Chinese behemoths Alibaba Group Holding Ltd. and Baidu Inc. —is up 11% year-to-date after a dramatic rally last week. The four FANG stocks added $251 billion in market value last week, their biggest gain on record dating to Facebook’s 2012 initial public offering. The S&P 500, in comparison, is down 13% in 2020 but has r
Read more

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. SHANGHAI, March 28, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Phase 2 study of its innovative PD-1 inhibitor HLX10 in patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) solid tumors that fail to respond to the standard therapy has met the primary endpoint. Henlius plans to file a New Drug Application (NDA) to the National Drug Products Administration (NMPA) for the treatment of MSI-H solid tumours based on the results from the Phase 2 trial of HLX10, which will be presented at upcoming medical conferences. Professor Shukui Qin of No.81 Hospital of People's Liberation Army and Professor Jin Li of Shanghai East Hospital affiliated to Shang
Read more